Core Insights - Pliant Therapeutics is undergoing a strategic restructuring, reducing its workforce by approximately 45% to extend its cash runway for late-stage clinical trials [1][3][4] - The company is awaiting topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast, expected in the second quarter of 2025, which will inform the next steps for the drug's development [2][3] Workforce Restructuring - The restructuring will impact all departments, but the company aims to maintain its late-stage clinical trial execution capabilities [3] - The process is expected to be substantially completed by the end of the second quarter of 2025 [3] Clinical Development - Bexotegrast is being developed for idiopathic pulmonary fibrosis (IPF) and has received Fast Track and Orphan Drug Designations from the FDA [4] - Pliant is also conducting a Phase 1 study for PLN-101095, targeting solid tumors, and has received clearance for a Phase 1 study of PLN-101325 for muscular dystrophies [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Pliant Therapeutics, Inc and its officers or directors [1] Company Developments - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial of bexotegrast due to recommendations from the independent Data Safety Monitoring Board [3] - Following this announcement, analysts from Wells Fargo and Citi downgraded Pliant, expressing uncertainty regarding the future of bexotegrast [3] Stock Performance - Pliant's stock price experienced a significant decline, falling by $4.72 per share, or 60.59%, closing at $3.07 per share on February 10, 2025 [4]

Core Viewpoint - Pliant Therapeutics, Inc is under investigation for potential securities fraud and unlawful business practices following a significant stock price drop after pausing a clinical trial for its drug bexotegrast [1][3]. Company Developments - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial of bexotegrast due to recommendations from the independent Data Safety Monitoring Board [3]. - Following this announcement, analysts from Wells Fargo and Citi downgraded Pliant, indicating uncertainty regarding the future of bexotegrast [3]. Stock Performance - After the announcement of the trial pause, Pliant's stock price fell by $4.72 per share, representing a 60.59% decrease, closing at $3.07 per share on February 10, 2025 [4].

Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investo ...

Core Insights - Pliant Therapeutics will present three scientific posters at the 2025 American Thoracic Society (ATS) International Conference in San Francisco from May 16-21, 2025 [1][2]. Group 1: Presentations at ATS Conference - Pliant has been selected for a featured oral presentation at the ATS 2025 Mini Symposiums program [2]. - The oral presentation titled "Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD Subtypes" will be presented by Dr. Johanna Schaub on May 19, 2025, from 2:15 p.m. to 4:15 p.m. Pacific Time [3]. - Two posters will be presented on May 21, 2025, focusing on plasma proteome analysis and single-cell profiling related to antifibrotic effects of Bexotegrast, both scheduled from 8:15 a.m. to 10:15 a.m. Pacific Time [3]. Group 2: Company Overview - Pliant Therapeutics is a late-stage biopharmaceutical company specializing in novel therapeutics for fibrotic diseases [4]. - The lead product candidate, Bexotegrast (PLN-74809), is an oral small molecule targeting idiopathic pulmonary fibrosis (IPF) and has received Fast Track and Orphan Drug Designations from the FDA [4]. - Pliant is also developing PLN-101095 for solid tumors and has regulatory clearance for a Phase 1 study of PLN-101325 targeting muscular dystrophies [4].

Core Insights - Pliant Therapeutics Inc. (PLRX) is a biotech company focused on developing therapeutics for fibrotic diseases and is currently in a cash-rich position despite facing a significant setback with its lead drug candidate [1] Company Overview - Pliant Therapeutics is engaged in the discovery and development of treatments specifically targeting fibrotic diseases [1] - The company has a strong cash position, which may provide it with the necessary resources to navigate challenges [1] Investment Perspective - The company is considered attractive for investors looking for small-cap stocks with high upside potential relative to downside risk [1] - The investment approach is value-based, with an openness to exploring special situations and short opportunities [1]

Shares of Pliant Therapeutics (PLRX) have plunged 88.5% in the past three months following recent setbacks in the clinical development program of its lead product candidate, bexotegrast (PLN-74809), for treating idiopathic pulmonary fibrosis (IPF). Bexotegrast is an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins.IPF is the most prevalent and severe type of progressive pulmonary fibrosis, impacting around 150,000 patients in the United States and more than three million worldwide.P ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Fa ...

Core Insights - Pliant Therapeutics, Inc. announced promising interim results from its Phase 1 clinical trial of PLN-101095, showing a 50% objective response rate in patients with advanced or metastatic solid tumors who are refractory to immune checkpoint inhibitors [2][5][6] Group 1: Clinical Trial Details - The trial is evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab in patients with ICI-refractory tumors [2][7] - Three partial responses were observed in cohort three at the highest tested dose of 1000 mg administered orally twice daily [2][5] - The trial has enrolled nine patients across three cohorts, with treatment durations of 14 days followed by combination therapy [3][5] Group 2: Efficacy Observations - Among the six patients treated at the 1000 mg BID dose, three confirmed partial responses were noted, with significant reductions in tumor sizes: 74% for NSCLC, 48% for cholangiocarcinoma, and 42% for melanoma [5][6] - Initial partial responses were observed at Week 10 for NSCLC, Week 34 for cholangiocarcinoma, and Week 18 for melanoma [5] Group 3: Safety and Tolerability - PLN-101095 was generally well tolerated across all doses tested, indicating a favorable safety profile [2][5][6] - The ongoing trial is currently enrolling the fourth cohort, which will evaluate PLN-101095 at a different dosing schedule of 1000 mg three times daily [6] Group 4: Company Background - Pliant Therapeutics is focused on developing novel therapeutics for fibrotic diseases, with PLN-101095 being a key candidate for treating solid tumors [8] - The company has received regulatory designations for its lead product candidate, bexotegrast, indicating its commitment to advancing innovative treatments [8]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]NEW YORK, March 13, 2025 /PRNewswire/ -- Faruqi & ...